Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zomedica Corp.'s SEC filings document current-report disclosures for an Alberta, Canada animal-health company. Its Form 8-K records include results of operations and financial condition, press-release exhibits, and Inline XBRL cover-page data. The filing record provides formal disclosure context for reported operating results, material events, exhibits, corporate jurisdiction, and public-company reporting under the Exchange Act.
Kevin Klass, Senior Vice President, Sales at Zomedica Corp., reported purchases of 60,723 shares on 08/11/2025 at $0.04, and 250,000 and 745,341 shares on 08/12/2025 at $0.04. Following these reported transactions, his beneficial ownership is shown sequentially as 4,260,753, 4,510,753 and 5,256,094 shares.
Zomedica Corp. reporting person Kevin Klass, Sr. Vice President of Sales, reported purchases on 08/11/2025 totaling 500,000 common shares in two transactions: 250,000 shares at $0.038 and 250,000 shares at $0.04. The filings show direct beneficial ownership rising to 4,200,030 shares. The Form 4 is signed on 08/12/2025. No derivative transactions are reported.
Kevin Klass, Senior Vice President of Sales at Zomedica Corp., reported acquiring 500,000 shares of common stock on 08/08/2025 at $0.04 per share under transaction code P (pursuant to a written plan). Following this transaction his reported beneficial ownership is 3,700,030 shares, held directly.